Paper Details

  1. Home
  2. Paper Details

Emerging reverse transcriptase inhibitors for HIV-1 infection.

Author: FichtenbaumCarl J, PannekSam, RaiMohammad A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Four new agents, GS-9131, MK-8591, Elsulfavirine and Doravirine, are showing promise as potential improvements to antiretroviral therapy (ART) for HIV. These newer agents have longer half-lives, more favorable adverse effect profiles, and fewer drug interactions.
Paper Details　
Original Abstract of the Article :
There are 36.7 million people living with HIV with 20.9 million having access to antiretroviral therapy (ART). Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) remain the 'backbone' of ART. However, the currently available nine NRTIs and five non-nucleoside reverse transcriptase inhibi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/29737220

データ提供：米国国立医学図書館（NLM）

New Hope on the Horizon: Emerging Reverse Transcriptase Inhibitors for HIV-1 Infection

This review explores the development of new reverse transcriptase inhibitors (RTIs) for the treatment of HIV-1 infection. While nucleoside/nucleotide RTIs (NRTIs) remain the backbone of current antiretroviral therapy (ART), the existing agents face challenges like resistance and side effects. This review discusses four new RTIs currently under development: GS-9131, MK-8591, Elsulfavirine, and Doravirine. These new agents offer potential improvements over existing RTIs with longer-acting durations, fewer side effects, and better resistance profiles.

A New Era in HIV-1 Treatment: Longer-Acting, Safer, and More Effective Agents

The development of these new RTIs holds exciting promise for the future of HIV-1 treatment. The longer-acting nature of MK-8591, for example, could significantly improve patient adherence to therapy. Doravirine offers a safer and more effective NNRTI with fewer side effects and a wider spectrum of activity. GS-9131 shows strong potency against various NRTI mutants, while Elsulfavirine boasts a longer half-life and potentially fewer side effects. These innovations contribute to a new era in HIV-1 treatment, characterized by more effective, safer, and more patient-friendly options.

Improving HIV-1 Treatment: Enhancing Adherence and Reducing Side Effects

The development of these new RTIs could significantly improve the lives of people living with HIV-1. By providing longer-acting and more effective treatment options with fewer side effects, these agents could potentially increase adherence to therapy, leading to improved patient outcomes and a better quality of life. This advancement in treatment could also contribute to a more comprehensive and effective approach to managing HIV-1 infection.

Dr. Camel's Conclusion

The emergence of these new RTIs is a testament to the ongoing progress in HIV-1 treatment. These new agents hold the potential to transform the landscape of HIV-1 care by offering more effective, safer, and more patient-friendly options. Just like the desert blooms after a rare rainfall, these innovations offer a glimmer of hope for a brighter future for individuals living with HIV-1.

Date :
  1. Date Completed 2018-10-18
  2. Date Revised 2023-09-28
Further Info :

Pubmed ID

29737220

DOI: Digital Object Identifier

NIHMS1501724

Related Literature

Article Analysis
・Side Effects of doravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.